Skip to content

Lobbying by AbbVie Corporation: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Corporation

AbbVie Corporation

Meetings this Parliament
39
With MPs
14
Since Nov 2021
105
Active registrations
1

Most recent reported meeting: Sep 23, 2026.

Who they meet

Since the current Parliament opened.

MPs

Institutions

  • Innovation, Science and Economic Development Canada (ISED)16
  • Health Canada (HC)15
  • House of Commons9
  • Treasury Board Of Canada Secretariat (TBS)7
  • Intergovernmental Affairs Secretariat (IGA)4
  • Global Affairs Canada (GAC)4
  • Finance Canada (FIN)4
  • Prime Minister's Office (PMO)3

Registrations in effect

In-house (corporation) In effect since Jul 2, 2026

Filed by Tanusree Misra, Vice-President and General Manager

Lobbyists

  • Adam Cook · Manager, Market Access and Government Affairs, Ontario & Federal Programs
  • Amelie McFadyen · Manager, Government Affairs and Policy
  • Arima Ventin · Head, Market Access and Government Affairs
  • Dana Corsen · Field Lead, Market Access & Government Affairs, Immunology
  • David Link · Field Lead, Market Access & Government Affairs - Specialty
  • Eric Pegolo · Manager, Market Access and Government Affairs, Ontario
  • Harold Just · Manager, Market Access and Government Affairs - Oncology
  • Herve Gaboury · Head, Market Access & HEOR, Oncology
  • Jean-Luc Fortier · Manager, Market Access and Government Affairs, Quebec
  • Jeff Onyskiw · Sr Manager, Market Access & Government Affairs – Saskatchewan, Manitoba, Federal Plans, Territories
  • Judith Mergl · Director, Regulatory Affairs
  • Lauren Fischer · Lead, Government Affairs & Policy
  • Reema Malhotra · Field Lead, Market Access & Government Affairs - Oncology
  • Sean Awalt · Manager, Market Access and Government Affairs, Atlantic
  • Stephanie Sauvageau · Head, Medical Affairs
  • Tanusree Misra · Vice-President and General Manager

Institutions they may lobby: Atlantic Canada Opportunities Agency (ACOA), Canadian Institutes of Health Research (CIHR), Correctional Service of Canada (CSC), Employment and Social Development Canada (ESDC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Immigration and Refugee Board (IRB), Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Invest in Canada Hub, National Defence (DND), National Research Council (NRC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Royal Canadian Mounted Police (RCMP), Senate of Canada, Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)

What they're lobbying on (19)
  • Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.
  • Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada.
  • Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
  • The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
  • Public Health Agency of Canada, regarding the federal response to the hepatitis C virus.
  • Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.
  • Federal Government Non Insured Health Benefits program with respect to reimbursement of a prescription medicine and changes in type of reimbursement
  • Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.
  • Communications with Heath Canada regarding modernization of the medical devices regulatory framework.
  • Communications with Health Canada regarding the evolution of the regulatory framework to address advanced therapeutic products.
  • Communications with Health Canada regarding the application of its nitrosamine guidelines.
  • Communications with Health Canada regarding modernization of clinical trials regulations, including diversity and inclusivity of clinical trials.
  • Communications with Health Canada regarding guidelines for pediatric action plans.
  • Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
  • Communications regarding the design and implementation of the federal Drugs for Rare Diseases strategy.
  • Communications regarding national pharmacare legislation, regulations, policies or programs.
  • Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime.
  • Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
  • Communications regarding access to and approval of medicines addressing the growing public health threat of antimicrobial resistance.

Registration 965103-15270-50. Look it up in the official Registry

Reported meetings

Spreadsheet

Filed by Tracey Ramsay (50), Rami Fayed (29), Tanusree Misra (17), Arima Ventin (9).

  • Reported by Tanusree Misra · In-house (corporation)

    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape. Read more

    The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.

    Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.

    Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.

    Official report

  • Reported by Tanusree Misra · In-house (corporation)

    • Maggie Chi · Member of Parliament
    • Nora Draper · Assistant to the Parliamentary Secretary, Health Canada (HC)
    Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape. Read more

    Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.

    Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.

    The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.

    Official report

  • Reported by Tanusree Misra · In-house (corporation)

    • Julie Harb · Policy Advisor, Prime Minister's Office (PMO)
    The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors. Read more

    Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.

    Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.

    Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.

    Official report

  • Reported by Tanusree Misra · In-house (corporation)

    • Mélanie Joly · Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, Innovation, Science and Economic Development Canada (ISED)
    • Claire Kennedy · Consul General, Global Affairs Canada (GAC)
    • Margaux MacDonald · Deputy Consul General and Senior Trade Commissioner, Global Affairs Canada (GAC)
    • Julien Rosan · Trade Commissioner, Global Affairs Canada (GAC)
    and 2 more
    • Udita Samuel · Deputy Chief of Staff, Innovation, Science and Economic Development Canada (ISED)
    • Mathis Denis · Director of Communications, Innovation, Science and Economic Development Canada (ISED)
    Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape. Read more

    The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.

    Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.

    Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.

    Official report

  • Reported by Tanusree Misra · In-house (corporation)

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
    Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada. Read more

    The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.

    Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.

    Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.

    Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.

    Official report

  • Reported by Tanusree Misra · In-house (corporation)

    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors. Read more

    The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.

    Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.

    Official report

  • Reported by Tanusree Misra · In-house (corporation)

    • Julie Harb · Policy Advisor, Prime Minister's Office (PMO)
    The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors. Read more

    Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.

    Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.

    Official report

  • Reported by Tanusree Misra · In-house (corporation)

    • Mark Wiseman · Ambassador of Canada to the United States, Global Affairs Canada (GAC)
    • Nadia Theodore · Deputy Ambassador of Canada to the United States, Global Affairs Canada (GAC)
    • Carlos Vanderloo · Minister-Counsellor, Economic, Global Affairs Canada (GAC)
    • Matt Fraser · Minister-Counsellor, Commercial and Senior Trade Commissioner, Global Affairs Canada (GAC)
    Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape. Read more

    The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.

    Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.

    Communication regarding free trade agreements as they relate to the biopharmaceutical industry.

    Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.

    Official report

  • Reported by Tanusree Misra · In-house (corporation)

    The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors. Read more

    Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.

    Official report

  • Reported by Tanusree Misra · In-house (corporation)

    • Oussama Nazih · Parliamentary Research Assistant, Senate of Canada
    Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape. Read more

    The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.

    Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.

    Official report

  • Reported by Tanusree Misra · In-house (corporation)

    • Karen Fortin · Executive Director, Indigenous Services Canada (ISC)
    • Michelle Mujoomdar · Manager, Policy, Indigenous Services Canada (ISC)
    • Dylan Radke · Pharmacist Consultant, Indigenous Services Canada (ISC)
    • Bradley Bennett · Pharmacist Consultant, Indigenous Services Canada (ISC)
    Communications with Health Canada regarding guidelines for pediatric action plans. Read more

    Federal Government Non Insured Health Benefits program with respect to reimbursement of a prescription medicine and changes in type of reimbursement

    Official report

  • Reported by Tanusree Misra · In-house (corporation)

    • Madeleine Fequiere · Consul General of Canada in Chicago, Global Affairs Canada (GAC)
    • Cory Olishansky · Consul and Trade Commissioner, Global Affairs Canada (GAC)
    • Julien Rosan · Life Sciences Trade Commissioner, Global Affairs Canada (GAC)
    Communication regarding free trade agreements as they relate to the biopharmaceutical industry. Read more

    Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.

    Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.

    Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.

    The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.

    Official report

  • Reported by Tanusree Misra · In-house (corporation)

    • Marjorie Michel · Minister of Health, Health Canada (HC)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Kaili Levesque · Associate Deputy Minister, Fisheries and Oceans Canada (DFO)
    and 10 more
    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    • Elizabeth Wong · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Fatouma Bah · Policy Advisor, Health Canada (HC)
    • Supriya Sharma · Acting Assistant Deputy Minister, Health Canada (HC)
    • Scott Lohnes · Senior Advisor, Health Canada (HC)
    Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors. Read more

    Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.

    The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.

    Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.

    Official report

  • Reported by Tanusree Misra · In-house (corporation)

    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    • Galen Richardson · Senior Advisor, Stakeholder Relations, Privy Council Office (PCO)
    Communication regarding free trade agreements as they relate to the biopharmaceutical industry. Read more

    The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.

    Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.

    Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada.

    Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.

    Official report

  • Reported by Tanusree Misra · In-house (corporation)

    • Kaili Levesque · Associate Deputy Minister, Fisheries and Oceans Canada (DFO)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    • Elizabeth Wong · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    and 6 more
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    • Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
    Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors. Read more

    Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.

    Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.

    The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.

    Official report

  • Reported by Tanusree Misra · In-house (corporation)

    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Jibril Hussein · Senior Policy Advisor, Health Canada (HC)
    and 6 more
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    • Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Kaili Levesque · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages. Read more

    Communication regarding free trade agreements as they relate to the biopharmaceutical industry.

    Official report

  • Reported by Tanusree Misra · In-house (corporation)

    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    and 3 more
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages. Read more

    Communication regarding free trade agreements as they relate to the biopharmaceutical industry.

    Official report

  • Reported by Arima Ventin · In-house (corporation)

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors. Read more

    Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.

    The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.

    Communication regarding free trade agreements as they relate to the biopharmaceutical industry.

    Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada.

    Official report

  • Reported by Arima Ventin · In-house (corporation)

    • Sony Perron · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Elizabeth Wong · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    and 6 more
    • Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    • Sarah O'Connor · A/ Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Celia Lourenco · A/ Assistant Deputy Minister, Health Canada (HC)
    Communication regarding free trade agreements as they relate to the biopharmaceutical industry. Read more

    Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.

    Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.

    Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.

    Official report

  • Reported by Arima Ventin · In-house (corporation)

    • Maggie Chi · Member of Parliament
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Elizabeth Wong · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    and 7 more
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    Communication regarding free trade agreements as they relate to the biopharmaceutical industry. Read more

    Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.

    Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.

    Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.

    Official report

  • Reported by Arima Ventin · In-house (corporation)

    • Marjorie Michel · Minister of Health, Health Canada (HC)
    • Sony Perron · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    and 6 more
    • Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
    Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape. Read more

    Communication regarding free trade agreements as they relate to the biopharmaceutical industry.

    Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.

    Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.

    Official report

  • Reported by Arima Ventin · In-house (corporation)

    • Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
    • Karim Bardeesy · Member of Parliament
    • Marjorie Michel · Minister of Health, Health Canada (HC)
    • Janice Charette · Chief Trade Negotiator to the United States, Global Affairs Canada (GAC)
    and 7 more
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Martin Moen · Assistant Associate Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
    • Manuela Tomic · Senior Policy Advisor, Office of the Minister of Industry, Innovation, Science and Economic Development Canada (ISED)
    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Shalene Curtis-Micallef · Deputy Minister of Health, Health Canada (HC)
    Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape. Read more

    Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.

    Communication regarding free trade agreements as they relate to the biopharmaceutical industry.

    Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.

    Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.

    The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.

    Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada.

    Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime.

    Official report

  • Reported by Arima Ventin · In-house (corporation)

    • Michael Ma · Member of Parliament
    • Ian King · Parliamentary Assistant, House of Commons
    Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape. Read more

    The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.

    Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.

    Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.

    Official report

  • Reported by Arima Ventin · In-house (corporation)

    • Justine Frame · Senior Policy Advisor, Health Canada (HC)
    Communication regarding free trade agreements as they relate to the biopharmaceutical industry. Read more

    Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.

    Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada.

    Official report

  • Reported by Arima Ventin · In-house (corporation)

    • Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Elizabeth Wong · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape. Read more

    Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.